GSK's Breo for asthma? FDA panel says yes–but only in adults
FiercePharma Good news for GlaxoSmithKline ($GSK): An FDA panel of experts says the efficacy and safety data for blockbuster wannabe Breo support the asthma indication it's gunning for in adults 18 and older. When it comes to children aged 12 to 17, though? UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents U.S. Panel Backs Glaxo's Breo for Asthma in Adults, Not Kids FDA panel backs Glaxo asthma drug for adults, not adolescents |
View full post on asthma – Google News